| 7.19 0.84 (13.23%) | 11-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.92  |
1-year : | 10.04 |
| Resists | First : | 7.64 |
Second : | 8.6 |
| Pivot price | 6.62 |
|||
| Supports | First : | 6.09 | Second : | 5.07 |
| MAs | MA(5) : | 6.55 |
MA(20) : | 6.67 |
| MA(100) : | 8.42 |
MA(250) : | 8.02 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 41.8 |
D(3) : | 25.4 |
| RSI | RSI(14): 51.4 |
|||
| 52-week | High : | 13.39 | Low : | 5.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MSLE ] has closed Bollinger Bands are 51.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.47 - 7.52 | 7.52 - 7.56 |
| Low: | 6.33 - 6.38 | 6.38 - 6.42 |
| Close: | 7.12 - 7.2 | 7.2 - 7.27 |
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Fri, 06 Nov 2026
Satellos Bioscience Inc. (MSLE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 06 Nov 2026
Satellos Bioscience Inc. (MSCL.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Thu, 05 Nov 2026
A November 6 Satellos (MSLE) call will cover its DMD study in boys ages 7, 8 or 9. - Stock Titan
Thu, 05 Nov 2026
A Friday call will discuss a Duchenne muscular dystrophy study for boys ages 7 to 9 - Stock Titan
Tue, 03 Nov 2026
Satellos Bioscience Inc. (MSLE) Seasonal returns chart - Yahoo Finance - Yahoo Finance Singapore
Mon, 02 Nov 2026
Satellos Bioscience Inc. (MSLE) Seasonal returns chart - Yahoo Finance UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 6.3 (%) |
| Held by Institutions | 49.7 (%) |
| Shares Short | 106 (K) |
| Shares Short P.Month | 89 (K) |
| EPS | -1.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -41.9 % |
| Return on Equity (ttm) | -70.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.45 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -3.69 |
| PEG Ratio | 0 |
| Price to Book value | 2.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|